Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 1 of 14 PagelD:
`21006
`
`EXHIBIT 23
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 2 of 14 PagelD:
`
`From: Bovyer, David
`To: Bradley J. Demuth; Boone, Brian; Brown, Liz Broadway; Edwards, Jordan; tscrivo@oslaw.com; Optum Insulin Team
`Cc: Peter Kohn; Steven Bloch - Silver Gol Teitell; Trevor Scheetz; Brandon Bogle; Josh Wackerly; Donald Ecklund; Jonathan F.
`
`Neumann; Sarah Deloach; apark@ktmc.com; jjacobson@ktmc.com; ErichSchork@robertslawfirm.us; Kelly Rinehart; "Karen Halbert";
`joanne@cicalaplic.com; dbuchanan@seegerweiss.com; mdickson@wcllp.com; bwicklund@wcllp.com; Bill Cash; Becca Timmons;
`Goetz, Dan; mskilken@weismanlaw.com; David C. Calvello
`
`Subject: RE: Insulin -- Emisar Interrogatory Responses
`Date: Thursday, June 5, 2025 10:20:46 AM
`Attachments: image001.png
`
`Emisar ESI Search Terms (A&B 2025.06.05).docx
`Emisar Search Term Redline (2025.06.05).docx
`
`CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you
`trust the sender.
`
`2]
`Brad:
`
`Please find attached Emisar’s counterproposal of search terms and a redline comparing Plaintiffs’ proposal and
`Emisar’s counterproposal.
`
`Best,
`David
`
`David Boyer
`
`Senior Associate
`
`ALSTON & BIRD
`
`1201 West Peachtree Street
`Atlanta, GA 30309
`
`+1404 881 7145 (O)
`
`+1 317509 0876 (M)
`David.Boyer@alston.com
`
`From: Bradley J. Demuth <bdemuth@farugilaw.com>
`
`Sent: Monday, June 2, 2025 4:55 PM
`
`To: Boyer, David <David.Boyer@alston.com>; Boone, Brian <Brian.Boone@alston.com>; Brown, Liz Broadway
`<Liz.Brown@alston.com>; Edwards, Jordan <Jordan.Edwards@alston.com>; tscrivo@oslaw.com; Optum Insulin
`Team <Optum.Insulin.Team@alston.com>
`
`Cc: Peter Kohn <pkohn@farugilaw.com>; Steven Bloch - Silver Golub & Teitell <sbloch@sgtlaw.com>; Trevor
`Scheetz <TScheetz@sperlingkenny.com>; Brandon Bogle <bbogle@levinlaw.com>; Josh Wackerly
`<josh@cicalapllc.com>; Donald Ecklund <decklund@carellabyrne.com>; Jonathan F. Neumann
`<jneumann@ktmc.com>; Sarah Deloach <sarahdeloach@robertslawfirm.us>; apark@ktmc.com;
`jjacobson@ktmc.com; ErichSchork@robertslawfirm.us; Kelly Rinehart <kellyrinehart@robertslawfirm.us>; 'Karen
`Halbert' <karenhalbert@robertslawfirm.us>; joanne@cicalaplic.com; dbuchanan@seegerweiss.com;
`mdickson@wcllp.com; bwicklund@wcllp.com; Bill Cash <bcash@levinlaw.com>; Becca Timmons
`<btimmons@Ievinlaw.com>; Goetz, Dan <DGoetz@weismanlaw.com>; mskilken@weismanlaw.com; David C.
`Calvello <dcalvello@farugilaw.com>
`
`Subject: RE: Insulin -- Emisar Interrogatory Responses
`
`EXTERNAL SENDER - Proceed with caution
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 3 of 14 PagelD:
`21008
`
`David: In addition to discussing the deficiencies in Emisar’s interrogatory responses on Thursday, we expect
`to also meet and confer regarding: (i) the open issues identified in my April 15 email, including search terms,
`as well as Emisar’s apparent inability to identify the “errors” in Search Nos. 2, 16, 21, and 26 that Emisar
`claims renders those searches un-runnable “as constructed”; (ii) Emisar’s failure to justify its designation of
`its March 28, 2025 letter as “Highly Confidential — Attorneys’ Eyes Only”; and (iii) Emisar’s designation of its
`April 30, 2025 interrogatory responses as “Highly Confidential - Attorneys’ Eyes Only,” which designation we
`challenge under Section 6 of the March 2024 Stipulated Confidentiality Order (ECF 117) as without basis.
`
`Best,
`Brad
`
`From: Bradley J. Demuth <bdemuth@farugilaw.com>
`Sent: Friday, May 30, 2025 3:48 PM
`
`To: Boyer, David <David.Boyer@alston.com>; Boone, Brian <Brian.Boone @alston.com>; Brown, Liz Broadway
`<Liz.Brown@alston.com>; Edwards, Jordan <Jordan.Edwards@alston.com>; tscrivo@oslaw.com; Optum Insulin
`
`Team <Optum.Insulin.Team@alston.com>
`
`Cc: Peter Kohn <pkohn@farugilaw.com>; Steven Bloch - Silver Golub & Teitell <sbloch@sgtlaw.com>; Trevor
`Scheetz <IScheetz@sperlingkenny.com>; Brandon Bogle <bbogle @levinlaw.com>; Josh Wackerly
`<josh@cicalapllc.com>; Donald Ecklund <decklund@carellabyrne.com>; Jonathan F. Neumann
`<jneumann@ktmc.com>; Sarah Deloach <sarahdeloach@robertslawfirm.us>; apark@ktmc.com;
`jjlacobson@ktmc.com; ErichSchork@robertslawfirm.us; Kelly Rinehart <kellyrinehart@robertslawfirm.us>; ‘Karen
`Halbert' <karenhalbert@robertslawfirm.us>; joanne@cicalapllc.com; dbuchanan@seegerweiss.com;
`mdickson@wcllp.com; bwicklund@wcllp.com; Bill Cash <bcash@levinlaw.com>; Becca Timmons
`<btimmons@levinlaw.com>; Goetz, Dan <DGoetz@weismanlaw.com>; mskilken@weismanlaw.com; David C.
`Calvello <dcalvello@farugilaw.com>
`
`Subject: RE: Insulin — Emisar Interrogatory Responses
`
`Thank you, David. | will send a calendar invite shortly for the June 5 1pm ET meet and confer you suggest.
`
`From: Boyer, David <David.Boyer@alston.com>
`
`Sent: Friday, May 30, 2025 8:40 AM
`
`To: Bradley J. Demuth <bdemuth@farugilaw.com>; Boone, Brian <Brian.Boone@alston.com>; Brown, Liz Broadway
`<Liz.Brown@alston.com>; Edwards, Jordan <Jordan.Edwards@alston.com>; tscrivo@oslaw.com; Optum Insulin
`Team <Optum.Insulin.Team@alston.com>
`
`Cc: Peter Kohn <pkohn@farugilaw.com>; Steven Bloch - Silver Golub & Teitell <sbloch@sgtlaw.com>; Trevor
`Scheetz <TScheetz@sperlingkenny.com>; Brandon Bogle <bbogle @levinlaw.com>; Josh Wackerly
`<josh@cicalapllc.com>; Donald Ecklund <decklund@carellabyrne.com>; Jonathan F. Neumann
`<jneumann@ktmc.com>; Sarah Deloach <sarahdeloach@robertslawfirm.us>; apark@ktmc.com;
`jlacobson@ktmc.com; ErichSchork@robertslawfirm.us; Kelly Rinehart <kellyrinehart@robertslawfirm.us>; 'Karen
`Halbert' <karenhalbert@robertslawfirm.us>; joanne@cicalapllc.com; dbuchanan@seegerweiss.com;
`mdickson@wcllp.com; bwicklund@wcllp.com; Bill Cash <bcash@levinlaw.com>; Becca Timmons
`<btimmons@levinlaw.com>; Goetz, Dan <DGoetz@weismanlaw.com>; mskilken@weismanlaw.com; David C.
`Calvello <dcalvello@farugilaw.com>
`
`Subject: RE: Insulin — Emisar Interrogatory Responses
`
`CAUTION: This Message originated from outside of the firm. Do not click on a link, open or enable any file unless you
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 4 of 14 PagelD:
`21009
`
`trust the sender.
`
`Brad:
`
`| am following up about Plaintiffs” May 21 letter regarding Emisar’s responses and objections to Plaintiffs’
`Interrogatories. We continue to review the letter, including Plaintiffs’ request that Emisar amend its responses, and
`a call to discuss would be helpful. Please let us know if Plaintiffs are available next Thursday (6/5) at 1 PM Eastern.
`
`Best,
`David
`
`David Boyer
`
`Senior Associate
`
`ALSTON & BIRD
`
`1201 West Peachtree Street
`Atlanta, GA 30309
`
`+1404 8817145 (0)
`
`+1 317 509 0876 (M)
`David.Boyer@alston.com
`
`From: Bradley J. Demuth <bdemuth@farugilaw.com>
`
`Sent: Wednesday, May 21, 2025 4:20 PM
`
`To: Boone, Brian <Brian.Boone @alston.com>; Brown, Liz Broadway <Liz.Brown@alston.com>; Boyer, David
`<David.Boyer@alston.com>; Edwards, Jordan <Jordan.Edwards@alston.com>; tscrivo@oslaw.com; Optum Insulin
`Team <Optum.Insulin.Team@alston.com>
`
`Cc: Peter Kohn <pkohn@farugilaw.com>; Steven Bloch - Silver Golub & Teitell <sbloch@sgtlaw.com>; Trevor
`Scheetz <IScheetz@sperlingkenny.com>; Brandon Bogle <bbogle @levinlaw.com>; Josh Wackerly
`<josh@cicalapllc.com>; Donald Ecklund <decklund@carellabyrne.com>; Jonathan F. Neumann
`<jneumann@ktmc.com>; Sarah Deloach <sarahdeloach@robertslawfirm.us>; apark@ktmc.com;
`jlacobson@ktmc.com; ErichSchork@robertslawfirm.us; Kelly Rinehart <kellyrinehart@robertslawfirm.us>; 'Karen
`
`Halbert' <karenhalbert@robertslawfirm.us>; joanne@cicalapllc.com; dbuchanan@seegerweiss.com;
`mdickson@wcllp.com; bwicklund@wcllp.com; Bill Cash <bcash@I|evinlaw.com>; Becca Timmons
`<btimmons@levinlaw.com>; Goetz, Dan <DGoetz@weismanlaw.com>; mskilken@weismanlaw.com; David C.
`
`Calvello <dcalvello@farugilaw.com>
`
`Subject: Insulin — Emisar Interrogatory Responses
`
`EXTERNAL SENDER - Proceed with caution
`
`Brian, Liz, and David: Please see attached.
`
`Best,
`Brad
`
`2]
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 5 of 14 PagelD:
`21010
`
`Bradley J. Demuth m Partner m Faruqi & Faruqi, LLP m 685 Third Avenue, 26th Floor m New York, NY 10017 m (T) 212-983-9330
`m (F) 212-983-9331 m www.farugilaw.com
`
`This message originates from the law firm of Faruqi & Faruqi, LLP. This email message and all attachments may contain legally privileged and
`confidential information intended solely for the use of the addressee. If you are not the intended recipient, you should immediately stop reading
`this message and delete it from your system. Any unauthorized reading, distribution, copying or other use of this message or its attachments is
`strictly prohibited. All personal messages express solely the sender's view and not those of Farugi & Faruqi, LLP. This message may not be copied
`
`or distributed without this disclaimer. If you received this message in error, please reply to the sender above immediately and permanently delete
`this message from your inbox.
`
`NOTICE: This e-mail message and all attachments may contain legally privileged and confidential
`information intended solely for the use of the addressee. If you are not the intended recipient, you are
`hereby notified that you may not read, copy, distribute or otherwise use this message or its attachments. If
`
`you have received this message in error, please notify the sender by email and delete all copies of the
`message immediately.
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 6 of 14 PagelD:
`21011
`
`Proposed Custodial Search Parameters for Emisar
`
`Search | Search Parameter
`No.
`
`1. (Admelog OR Adylxyin OR Apidra OR Aspart* OR Basaglar OR Basal OR Degludec OR
`Detemir OR Diabet* OR Fiasp OR Flexpen OR Flextouch OR Glargine* OR GLP* OR
`Humalog OR Humulin OR Insulin* OR Kwikpen OR Lantus OR Levemir OR Lins OR
`Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR Novofine OR Novolin
`OR Novolog OR NovoPen OR NovoTwist OR Ozempic OR PenFill OR “"Private Label*"
`OR Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee OR Soliqua OR
`SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR Tresiba OR Trulicity
`OR Victoza OR Xultophy-fthe-“Biabetes-MedicationTtermsy)
`
`2. “+-of~-OR-(AF OR MAF OR aggregat* OR agreement OR "Anchor Date”" OR arbitrage OR
`AWP OR "Best Price”" OR Bid OR "Budget Impact Model*" OR BIM OR Bundl* OR (client
`w/2 (value OR share)) OR concession OR contract OR (dgeatertermsheet w/3
`sheet(deal OR term)) OR discount®* OR EBIT* OR "fair market value*" OR (fee* w/3
`(ponal OR enterprlse OR admln* OR data)) OR gateway OR grid* OR {gross/5vatte SR
`: ereh-OR-"incremental value”" OR
`“Indlrect Purchase”" OR Inflat* OR “Insulln Cost Evaluator”" OR "Integrated Health
`Services™" OR IHS OR Keep OR kept OR "Market Share*" OR matrix OR matrices OR
`"Most Favored Nation”er" OR MFN OR {ret/3-costfOR{ret/Svatue-OR-gainr-ORcost
`OR-ctientyOR-"Net Effective” OR "Net Net”" OR "pass-through" OR "pass through" &+
`
`OR "pass-thru-er-"_OR "pass thru" OR Payment* OR {Pharma+5reventeOR-"Pharmacy
`Supplemental*" OR Pric* OR "Price Predictability*" OR "Price Protection*" OR Profit*
`OR "Promotional Allowances”" OR Rate* OR Rebat* OR "Reconciliation Report*" OR
`Retain* OR Retention OR Revenue* OR "Safe Harbor-SR-femptate/3vatter" OR
`
`Upside OR Utlllzatlon OR*“"value extractlonfl" OR “WAC—[-thei%anufaetuferPayment
`
`Llspro* OR L|X|senat|de OR Logs OR Mounjaro OR Novofine OR Novolln OR Novolog OR
`NovoPen OR NovoTwist OR Ozemplc OR PenFill OR "Private Label“ OR Relion OR
`
`3. ((inflat* OR (price* w/1 increas*)) w/10 (opportunit* OR upside* OR gain* OR gross OR
`margin* OR favorabl* OR unfavorabl* OR benefit*)) w/30 (Admelog OR Adylxyin OR
`Apldra OR Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Dlabet* OR
`
`4. ((profit* OR margln* OR gain* OR share* OR keep* OR kept OR retain* OR retentlon OR
`split* OR 101l OR (pass* w/3 (through or thru or back)) OR "pass-thru" OR "pass-
`through" OR passthru OR passthrough OR "PT" OR "pass-back" OR passback) w/5 (net
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 7 of 14 PagelD:
`21012
`
`OR gross OR assum* OR estimat* OR averag* OR AVG OR rebat* OR (fee* w/3 (admin*
`OR GPO OR participat* OR manufactur* OR portal OR enter* OR gateway OR data)))
`OR AF OR MAF OR protect*) w/30 (Admelog OR Adylxyin OR Apidra OR Aspart* OR
`Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR Flexpen OR
`Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR Kwikpen OR
`antus OR Levemir OR Lins OR L|raglut|de OR Lispro* OR Lixisenatide OR Logs OR
`
`5. i(proflt* OR margln* OR gain* OR earn* OR share* OR gross OR net OR upside OR IOl
`OR EBIT* OR calculat*) w/5 (rebat* OR (fee* w/3 admin* OR GPO OR Participat* OR
`manufactur* OR portal OR enter* OR gateway OR data) ORAFOR MAF OR protect*))
`
`OR Novolog OR NovoPen OR NovoTW|st OR Ozemglc OR PenF|ll OR "Private Label" OR
`Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee OR Soliqua OR
`SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR Tresiba OR Trulicity
`OR Victoza OR Xultophy)
`6. (keep* OR kept OR retain* OR retention OR earn* OR share* OR profit* OR margin* OR
`101 OR EBIT*) w/5 (("shared savings" OR ((flat OR fix*) w/3 (dollar* OR rebat* OR
`percentage*)) OR reinvest* OR split* OR guarantee* OR (pass* w/3 (through erOR thru
`otOR back)) OR "pass-thru” OR "pass-through" OR passthru OR passthrough OR PT OR
`"pass-back"” OR passback) w/5 (client* OR contract*)) AND (Admelog OR Adylxyin OR
`Apidra OR Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR
`
`Fiasp OR Flexpen OR Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR
`Insulln* OR Kwikpen OR Lantus OR Levemir OR Lins OR L|raglut|de OR Lispro* OR
`
`O
`
`Mgwfldepartmem ofjustlce”" OR “"DOJ”" OR Congress* OR
`HOGR OR Senat* OR DOL OR "Department of Labor" OR "Labor Dep*") w/25
`
`(payment* OR rebat* OR exclu* OR block OR payoff* OR bribe* OR kickback* OR (kick
`w/2 back) OR fee OR fees OR discount*)) AND NOT (“"anti-kickback*" OR
`antikickbacky)
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 8 of 14 PagelD:
`21013
`
`9. (Admelog OR Adylxyin OR Apidra OR Aspart* OR Basaglar OR Basal OR Degludec OR
`Detemir OR Diabet* OR Fiasp OR Flexpen OR Flextouch OR Glargine* OR GLP* OR
`Humalog OR Humulin OR Insulin* OR Kwikpen OR Lantus OR Levemir OR Lins OR
`Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR Novofine OR Novolin
`OR Novolog OR NovoPen OR Novolwist OR Ozempic OR PenFill OR "Private Label" OR
`Relion OR Rezvoglar OR R;gbelsus OR Semaglutlde OR Semglee OR Sollgua OR
`
`Mw(maymem* OR rebat* OR exclu* OR block OR payoff*
`OR bribe* kickback* OR (kick w/2 back) OR fee OR fees OR discount* OR formular* OR
`PDL OR“"performance drug list*") w/10 (discretion*)) AND NOT (“"anti-kickback*" OR
`antikickbacky)
`
`10.
`
`SoloSTAR OR Stegaltro OR Tanzeum OR T|rzeQat|de OR TOU|eO OR Tre3|ba OR Trulicity
`
`OR Victoza OR Xultophy) AND (breach w/5 (payment* OR rebat* OR exclu* OR block
`OR payoff* OR bribe* OR kickback* OR (kick w/2 back) OR fee OR fees OR discount*
`
`OR formular* OR PDL OR “"performance drug list*")-w/5breach) AND NOT (“"anti-
`kickback*" OR antikickbacky)
`
`11. | fAny bBiabetes MedicationfermfromSearch-1}(Admelog OR Adylxyin OR Apidra OR
`Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR
`Flexpen OR Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR
`Kwikpen OR Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR
`Logs OR Mounjaro OR Novofine OR Novolin OR Novolog OR NovoPen OR NovoTwist OR
`Ozempic OR PenfFill OR "Private Label" OR Relion OR Rezvoglar OR Rybelsus OR
`
`Semaglutlde OR Semglee OR Sollgua OR SoloSTAR OR Stegaltro OR Tanzeum OR
`w/25 (forecast*
`
`OR model* OR budget* OR prOJect* OR est|mat* OR assum* OR analy* OR
`benchmark* OR trend* OR plan* OR strat* OR LRP OR share* OR trade OR upside OR
`base OR comparable* OR (pric* w/5 (erod* ©fOR erosion)))
`12. | (("lily.com" OR "novonordisk.com" OR "novo.dk" OR "sanofi.com" OR "sanofi-
`aventis.com" OR "aventis.com" OR "sanofipasteur.fr") AND (ESI OR "Express Scripts"
`OR "Express-Scripts" OR Evernorth OR Medco OR Cigna OR Aetna OR CVS OR
`Caremark OR CMX OR Optum* OR Orx OR UHG OR "evernorth.com" OR "medco.com”
`OR "thecignagroup.com" OR "cigna.com" OR "express-scripts.com" OR
`"cvshealth.com" OR "medco.com" OR "optum.com" OR "optumrx.com" OR "uhc.com"
`OR "uhg.com" OR "unitedhealthgroup.com")) w/30 (Admelog OR Adylxyin OR Apidra OR
`Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR
`Flexpen OR Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR
`Kwikpen OR Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR
`Logs OR Mounjaro OR Novofine OR Novolin OR Novolog OR NovoPen OR NovoTwist OR
`Ozempic OR PenfFill OR "Private Label" OR Relion OR Rezvoglar OR Rybelsus OR
`Semaglutide OR Semglee OR Soliqua OR SoloSTAR OR Stegaltro OR Tanzeum OR
`Tirzepatide OR Toujeo OR Tresiba OR Trulicity OR Victoza OR Xultophy)
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 9 of 14 PagelD:
`21014
`
`13. | (("evernorth.com” OR "medco.com” OR "thecignagroup.com' OR "cigna.com" OR
`"express-scripts.com" OR "cvshealth.com" OR "medco.com" OR "optum.com" OR
`"optumrx.com” OR "uhc.com” OR "uhg.com" OR "unitedhealthgroup.com") AND (Lilly
`OR LLY OR EliLilly OR (ELli w/2 Lilly) OR (Eli w/2 Lily) OR Novo* OR Nordisk OR NVN OR
`NVO* OR NNI OR Sanofi OR SFI OR Aventis OR SAV OR SNY OR "lilly.com”" OR
`"novonordisk.com" OR "novo.dk" OR "sanofi.com" OR "sanofi-aventis.com" OR
`
`"aventrs com" OR "sanofrpasteurerMg%@%M
`
`14. | (ESI OR "Express Scrlpts" OR "Express Scrlpts" OR Evernorth OR Medco OR Cigna OR
`Aetna OR CVS OR Caremark OR CMX OR "evernorth.com" OR "medco.com" OR
`"thecignagroup.com" OR "cigna.com" OR "express-scripts.com" OR "cvshealth.com"
`OR "medco.com”) w/30 (Admelog OR Adylxyin OR Apidra OR Aspart* OR Basaglar OR
`Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR Flexpen OR Flextouch OR
`Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR Kwikpen OR Lantus OR
`Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR
`Novofine OR Novolin OR Novolog OR NovoPen OR Novolwist OR Ozempic OR PenfFill
`OR "Private Label" OR Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee
`OR Soliqua OR SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR
`Tresiba OR Trulicity OR Victoza OR Xultophy)
`15. | (("zinchealthservices.com" OR zinc OR "ascenthealthservices.com" OR ascent OR AHS
`OR emisar OR CAPs or aggregat* OR GPO OR "group purchasing") w/25 (purpose OR
`point OR intent* OR function* OR effect* OR trans* OR visab* OR shield* OR prevent*
`OR obstruct* OR obscur* OR conceal* OR mask* etOR camo* OR “"black box*" OR
`hurdle* OR hinder* OR hindr* OR complic* OR block* OR hid* OR undisclosed OR
`
`secret OR "|n writing" OR txt OR "text me" OR "call me")j)%(%g%fldm
`
`16.
`
`ImQact Model" OR "BIM" OR Bundl* OR gcllent w/2 (value OR share)) OR concession O
`contract OR (sheet w/3 (deal OR term)) OR discount* OR EBIT* OR "fair market value"
`OR (fee* w/3 (portal OR enterprise OR admin* OR data)) OR gateway OR grid* OR
`"incremental value" OR "Indirect Purchase" OR Inflat* OR "Insulin Cost Evaluator" OR
`"Integrated Health Services" OR IHS OR Keep OR kept OR "Market Share" OR matrix OR
`matrices OR "Most Favored Nation" OR MFN OR "Net Effective" OR "Net Net" OR "pass-
`
`'Pharmacy Supplemental” OR Pric* OR "Price Predictability” OR "Price Protection"” OR
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 10 of 14 PagelD:
`21015
`
`Profit* OR "Promotional Allowances" OR Rate* OR Rebat* OR "Reconciliation Report"
`OR Retain* OR Retention OR Revenue* OR "Safe Harbor" OR Upside OR Utilization OR
`"value extraction" OR "WAC") w/25 (purpose OR point OR intent* OR function* OR
`effect* OR trans* OR visab* OR shield* OR prevent* OR obstruct* OR obscur* OR
`conceal* OR mask* or camo* OR “"black box*" OR hurdle* OR hinder* OR hindr* OR
`
`block* OR hid* OR und|sclosed OR secret OR "in writing" OR txt OR "text me" OR "call
`
`17. | ((complain* OR investigat* OR conflict* OR align* OR accounting* OR audit* OR
`inquir* OR concern* OR error* OR ((behalf OR interest* OR goal* OR mission* OR rely
`OR reliance) w/5 (customer* 6+OR client* orOR plan*)) OR (Trust* w/5 (advi* OR source
`OR resource OR earn* OR partner*)) OR ((Uniqu* OR only) w/5 (exper* OR negotiat* OR
`skill* OR capab*)) OR ((client* OR customer* OR plan*) w/5 (pledg* OR satisf* OR
`trust* OR loyal* OR confid*)) OR (Industr* w/5 (best 6+OR lead*)) w/5 rebat*) w/10 (ESI
`OR "Express Scripts" OR "Express-Scripts" OR Evernorth OR Medco OR Cigna OR Aetna
`OR CVS OR Caremark OR CMX OR Optum* OR Orx OR UHG OR "evernorth.com" OR
`"medco.com” OR "thecignagroup.com" OR "cigna.com" OR "express-scripts.com” OR
`"cvshealth.com" OR "medco.com” OR "optum.com" OR "optumrx.com" OR "uhc.com"
`OR "uhg.com" OR "unitedhealthgroup.com™)) AND (Admelog OR Adylxyin OR Apidra OR
`Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR
`Flexgen OR Flextouch OR Glarglne* OR GLP* OR Humalog OR Humulin OR Insulln* OR
`
`18. gcomplaln* OR mvestlgat* OR confllct* OR align* OR accountlng* OR audit* OR
`inquir* OR concern* OR error* OR ((behalf OR interest* OR goal* OR mission* OR rely
`OR reliance) w/5 (customer* 6+OR client* orOR plan*)) OR (Trust* w/5 (advi* OR source
`OR resource OR earn* OR partner*)) OR ((Uniqu* OR only) w/5 (exper* OR negotiat* OR
`skill* OR capab*)) OR ((client* OR customer* OR plan*) w/5 (pledg* OR satisf* OR
`trust* OR loyal* OR confid*)) OR (Industr* w/5 (best 6rOR lead*)-w/5+rebat*)) w/10 (Lilly
`OR LLY OR EliLilly OR (ELli w/2 Lilly) OR (Eli w/2 Lily) OR Novo* OR Nordisk OR NVN OR
`NVO* OR NNI OR Sanofi OR SFI OR Aventis OR SAV OR SNY OR "lilly.com" OR
`"novonordisk.com" OR "novo.dk" OR "sanofi.com" OR "sanofi-aventis.com" OR
`"aventis.com" OR "sanofipasteur.fr")) AND (Admelog OR Adylxyin OR Apidra OR Aspart*
`OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR Flexpen OR
`Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR Kwikpen OR
`Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR Logs OR
`Mounjaro OR Novofine OR Novolin OR Novolog OR NovoPen OR Novolwist OR
`Ozempic OR PenFill OR "Private Label" OR Relion OR Rezvoglar OR Rybelsus OR
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 11 of 14 PagelD:
`21016
`
`Semaglutide OR Semglee OR Soliqua OR SoloSTAR OR Stegaltro OR Tanzeum OR
`Tirzepatide OR Toujeo OR Tresiba OR Trulicity OR Victoza OR Xultophy)
`
`19. | ((complain* OR investigat* OR conflict* OR align* OR accounting* OR audit* OR
`inquir* OR concern* OR error* OR ((behalf OR interest* OR goal* OR mission* OR rely
`ORreliance) w/5 (customer* +OR client* 6rOR plan*)) OR (Trust* w/5 (advi* OR source
`OR resource OR earn* OR partner*)) OR ((Uniqu* OR only) w/5 (exper* OR negotiat* OR
`skill* OR capab*)) OR ((client* OR customer* OR plan*) w/5 (pledg* OR satisf* OR
`trust* OR loyal* OR confid*)) OR (Industr* w/5 (best 6rOR lead*)-w/5rebat*)) w/10 (zinc
`OR ascent OR AHS OR emisar OR GPO OR "group purchasmg"p&(%g@
`
`20. | ((legisl* 6rOR regulat*) w/10 ("pharmacy benefit manager*" OR PBM* OR rebat* OR
`aggregat* OR GPO OR "group purchasing" OR zinc OR ascent OR AHS OR emisar)) w/30
`(Admelog OR Adylxyin OR Apidra OR Aspart* OR Basaglar OR Basal OR Degludec OR
`Detemir OR Diabet* OR Fiasp OR Flexpen OR Flextouch OR Glargine* OR GLP* OR
`Humalog OR Humulin OR Insulin* OR Kwikpen OR Lantus OR Levemir OR Lins OR
`Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR Novofine OR Novolin
`OR Novolog OR NovoPen OR Novolwist OR Ozempic OR PenFill OR “Private Label” OR
`Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee OR Soliqua OR
`SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR Tresiba OR Trulicity
`OR Victoza OR Xultophy)
`
`21. | (("Pharmaceutical Research and Manufacturers" OR "Pharmaceutical Care
`Management ASSOC|at|on" OR Phrma OR"PCMA" OR "phrma org" OR™" pcma org") w/25
`
`Allowances" OR Rate* OR Rebat* OR "Reconciliation Report" OR Retain* OR Retention
`OR Revenue* OR "Safe Harbor" OR Upside OR Utilization OR "value extraction" OR
`"WAC")) AND (Admelog OR Adylxyin OR Apidra OR Aspart* OR Basaglar OR Basal OR
`Degludec OR Detemir OR Diabet* OR Fiasp OR Flexpen OR Flextouch OR Glargine* OR
`GLP* OR Humalog OR Humulin OR Insulin* OR Kwikpen OR Lantus OR Levemir OR Lins
`OR Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR Novofine OR
`Novolin OR Novolog OR NovoPen OR NovoTwist OR Ozempic OR PenFill OR "Private
`Label" OR Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee OR Soliqua
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 12 of 14 PagelD:
`21017
`
`OR SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR Tresiba OR
`Trulicity OR Victoza OR Xultophy)
`
`22. | (("Pharmaceutical Research and Manufacturers" OR "Pharmaceutical Care
`Management Association"” OR Phrma OR PCMA OR "phrma.org" OR "pcma.org") w/25
`(ESI OR "Express Scripts" OR "Express-Scripts" OR Evernorth OR Medco OR Cigna OR
`Aetna OR CVS OR Caremark OR CMX OR Optum* OR Orx OR UHG OR "evernorth.com”
`OR "medco.com" OR "thecignagroup.com" OR "cigna.com" OR "express-scripts.com”
`OR "cvshealth.com" OR "medco.com” OR "optum.com” OR "optumrx.com” OR
`
`"uhc com" OR "uhg. com" OR "umtedhealthgroup comMMg%@@
`
`23. | ((" PharmaceutlcalResearch and Manufacturers"OR PharmaceuncalCare
`Management Association" OR Phrma OR PCMA OR "phrma.org" OR "pcma.org") w/25
`(Lilly OR LLY OR EliLilly OR (ELli w/2 Lilly) OR (Eli w/2 Lily) OR Novo* OR Nordisk OR NVN
`OR NVO* OR NNI OR Sanofi OR SFI OR Aventis OR SAV OR SNY OR "lilly.com" OR
`"novonordisk.com" OR "novo.dk" OR "sanofi.com" OR "sanofi-aventis.com" OR
`"aventis.com" OR "sanofipasteur.fr")) w/30 (Admelog OR Adylxyin OR Apidra OR
`Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR
`Flexpen OR Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR
`Kwikpen OR Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR
`Logs OR Mounjaro OR Novofine OR Novolin OR Novolog OR NovoPen OR NovoTwist OR
`Ozempic OR PenfFill OR "Private Label" OR Relion OR Rezvoglar OR Rybelsus OR
`Semaglutide OR Semglee OR Soliqua OR SoloSTAR OR Stegaltro OR Tanzeum OR
`Tirzepatide OR Toujeo OR Tresiba OR Trulicity OR Victoza OR Xultophy)
`24. | (("Pharmaceutical Research and Manufacturers" OR "Pharmaceutical Care
`Management Association" OR Phrma OR PCMA OR "phrma. org" OR "pcma org") w/25
`(zinc OR ascent OR AHS OR emisar
`
`25.
`
`Flextouch OR Glargme* OR GLP* OR Humalog OR Humulm OR Insulln* OR KW|ern OR
`
`Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR Logs OR
`Mounjaro OR Novofine OR Novolin OR Novolog OR NovoPen OR Novolwist OR
`Ozempic OR PenFill OR “Private Label” OR Relion OR Rezvoglar OR Rybelsus OR
`Semaglutide OR Semglee OR Soliqua OR SoloSTAR OR Stegaltro OR Tanzeum OR
`Tirzepatide OR Toujeo OR Tresiba OR Trulicity OR Victoza OR Xultophy)
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25 Page 13 of 14 PagelD:
`21018
`
`26. | fAnyManufacture PaymentTermfromSearch2}(("AF" OR "MAF" OR aggregat* OR
`agreement OR "Anchor Date" OR arbitrage OR "AWP" OR "Best Price" OR Bid OR
`
`"Budget Impact Model" OR "BIM" OR Bundl* OR (client w/2 (value OR share)) OR
`concession OR contract OR (sheet w/3 (deal OR term)) OR discount* OR EBIT* OR "fair
`market value" OR (fee* w/3 (portal OR enterprise OR admin* OR data)) OR gateway OR
`grid* OR "incremental value" OR "Indlrect Purchase" OR Inflat* OR "Insulin Cost
`
`%wlw/5 (payor* OR payer* OR TPF’ 0fQB insur*
`OR "self-fund*" OR "self-insur*" OR sponsor* OR plan* OR consultant* OR client* OR
`
`OR GLP* OR Humalog OR Humulln OR Insulln* OR KW|ern OR Lantus OR Levemlr OR
`
`Lins OR Liraglutide OR Lispro* OR Lixisenatide OR Logs OR Mounjaro OR Novofine OR
`Novolin OR Novolog OR NovoPen OR NovoTwist OR Ozempic OR PenFill OR "Private
`Label" OR Relion OR Rezvoglar OR Rybelsus OR Semaglutide OR Semglee OR Soliqua
`OR SoloSTAR OR Stegaltro OR Tanzeum OR Tirzepatide OR Toujeo OR Tresiba OR
`Trul|C|t¥ OR Victoza OR Xultogh¥)
`
`27.
`
`28. | fAny DiabetesMedicationTermfrom-Search-1}(Admelog OR Adylxyin OR Apidra OR
`Aspart* OR Basaglar OR Basal OR Degludec OR Detemir OR Diabet* OR Fiasp OR
`Flexpen OR Flextouch OR Glargine* OR GLP* OR Humalog OR Humulin OR Insulin* OR
`Kwikpen OR Lantus OR Levemir OR Lins OR Liraglutide OR Lispro* OR Lixisenatide OR
`Logs OR Moun|aro OR Novoflne OR Novolin OR Novolog OR NovoPen OR NovoTwist OR
`O
`
`[ W/%{&UQVM\
`OR IMS OR SDI OR Symphony OR Verlspan OR "Walters Kluwer" OR MMIT OR
`"Decisions Resources" OR DRG OR BusinessOne OR IPS OR NPA OR Xponent NSP OR
`NDTI OR VONAY)
`
`
`
`
`
`
`
`
`
`Case 2:23-md-03080-BRM-LDW Document 793 Filed 11/05/25
`
`21019
`
`Page 14 of 14 PagelD:
`
`Summary report:
`
`8:44:51 AM
`
`Litera Compare for Word 11.8.0.56 Document comparison done on 6/5/2025
`
`Style name: Default Style
`
`Intelligent Table Comparison: Active
`
`Original filename: Emisar ESI Search Terms.docx
`
`Modified filename: Emisar ESI Search Terms (A&B 2025.06.05).docx
`
`Changes:
`
`Add
`
`338
`
`Dot
`
`o]
`(=)
`
`Meve-From
`
`Move To
`
`Table Insert
`
`iy
`
`Table moves to
`
`Embedded Graphics (Visio, ChemDraw, Images etc.)
`
`Embedded Excel
`
`Format changes
`
`Total Changes:
`
`Lo £=1 =] [=] [==] [==] (=] [e] Few] Few)
`
`
`
`
`
`
`
`
`
`